A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.
NCT ID: NCT00415428
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2776 participants
OBSERVATIONAL
2007-01-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Patient Education on Compliance and Cardiovascular Risk Parameters
NCT02096887
Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease
NCT00323258
Effect of Peer-mentor Mediated Interventions on Cardiovascular Risk Factors at Worksites
NCT02388542
The Educational Effectiveness for Atrial Fibrillation Patients Under Warfarin Treatment
NCT02871765
Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
NCT00399880
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1.
Patient adherence to national educational guidelines.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patient adherence to national educational guidelines.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with known CVD diagnosed \> or = 6 months before inclusion
* Previous myocardial infarction
* Ischemic heart disease (stable and unstable angina pectoris)
* Ischemic apoplexy
* Peripheral arterial disease
* And/Or
* Subjects with T2D diagnosed \> or = 6 months before inclusion
* At least 50% of the subjects had to have CVD as the primary diagnosis. It was allowed for a secondary diagnosis to be \<6 months before inclusion.
Exclusion Criteria
* Life expectancy of \< or = 2 years
* Unable/unwilling to understand/follow instructions
* Taking part in a clinical study involving an investigational drug
* Followed by a specialist for their CVD and/or T2D at the time of inclusion in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581154
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.